Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray [Yahoo! Finance]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
See our latest analysis for Milestone Pharmaceuticals. The FDA approval lands at an interesting time for investors, with Milestone's 30 day share price return of 17.25 percent and year to date share price return of 8.06 percent pointing to improving momentum, even as the 1 year total shareholder return of 28.85 percent contrasts with weaker multi year total shareholder returns. If this kind of regulatory catalyst has your attention, it could be a good moment to explore other innovative opportunities across healthcare stocks for fresh ideas beyond Milestone. With shares still trading below analyst targets despite a major first product approval, is Milestone an overlooked value in cardiovascular care, or has the market already discounted years of potential CARDAMYST driven growth? Milestone shares last closed at $2.35, but on a price to book basis they trade at a steep premium to both peers and the wider pharmaceuticals space. The price to book ratio compares a company's mark
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher [Seeking Alpha]Seeking Alpha
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Cowen Inc from a "hold" rating to a "buy" rating.MarketBeat
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock.MarketBeat
MIST
Earnings
- 11/12/25 - Beat
MIST
Sec Filings
- 12/15/25 - Form 8-K
- 12/11/25 - Form 4
- 11/14/25 - Form SCHEDULE
- MIST's page on the SEC website